- Company
- Rx amount for Ezetimibe·Statin increased 5 times in 4 years
- by Chon, Seung-Hyun Apr 28, 2020 06:23am
- The combination of Statin and Ezetimibe in the hyperlipidemic drug market is rapidly increasing. Over the past four years, outpatient prescription amount has increased five times. It was prescribed more than &8361;100 billion in the first quarter. The prescription scale of the combination of 'Rosuvastatin·Ezetimibe' such as Hanmi's 'Rosuzet
- Company
- Xarelto-Eliquis follow Lixiana dominating NOAC market
- by Kim, Jin-Gu Apr 27, 2020 06:11am
- Lixiana has reaffirmed its dominance in the non-vitamin K antagonist oral anticoagulant (NOAC) market. Eliquis has gotten close to taking over the second place from Xarelto with ever more intense competition in the market,. First released in last June, generic products of Eliquis are expanding their pies. Currently, 12 products are released
- Company
- “Considering treatment options for ankylosing spondylitis”
- by Eo, Yun-Ho Apr 27, 2020 06:10am
- In the autoimmune disease area, where tumor necrosis factor alpha (TNF alpha) inhibitor is leading the prescription market, various options of oral Janus kinase (JAK) inhibitors have been released so far. Guidelines on treating ankylosing spondylitis and spondylarthritis in Korea and other countries have a tendency to emphasize starting
- Policy
- 19 new drugs & 1 new medical device were approved
- by Lee, Tak-Sun Apr 27, 2020 06:10am
- In the first quarter, 19 new drugs and 1 newly developed medical device were approved. The MFDS (Minister Eui-kyung Lee) made the announcement on the 23rd, when it released a list of new medical products that were first approved in Korea, such as new drugs and newly developed medical devices, in the first quarter of 2020. Previously, the s
- Policy
- It has been successful in expanding the coverage of new drug
- by Lee, Jeong-Hwan Apr 27, 2020 06:09am
- It was evaluated that the government has achieved success in strengthening generic management, such as strengthening guarantees like new drugs for anticancer and rare diseases last year, and announcing plans to revise the generic drug pricing system. In the case of Ranitidine, a gastrointestinal drug containing carcinogenic substance NDMA,
- Company
- Keytruda to finally get Cancer Committee nod after 2years?
- by Eo, Yun-Ho Apr 24, 2020 06:27am
- After waiting for two long years, MSD is committed to receive the Korean health authority’s approval on Keytruda’s coverage expansion this time. According to pharmaceutical industry sources, the Health Insurance Review and Assessment Service (HIRA) Cancer Deliberation Committee’s deliberation on Keytruda (pembrolizumab) has been schedu
- Policy
- Chong Kun Dang’s Esoduo, registered additional patents
- by Lee, Tak-Sun Apr 24, 2020 06:26am
- Chong Kun Dang’s anti-ulcer agent Esoduo (Esomeprazole magnesium trihydrate), has added an additional patent. Basically, if the original drug patent is listed on the MFDS’ patent list, late candidates must succeed in the patent challenge to ensure early release. Items that are commercially available without patent challenge may be subje
- Company
- The KPBMA promotes of co-development of COVID-19 treatments
- by Lee, Seok-Jun Apr 24, 2020 06:26am
- The KPBMA promotes joint development of COVID-19 treatment. This is the first 'co-investment and joint development' method among member companies. The KPBMA held a board of directors meeting on the 21st to discuss this. Participants decided to aggregate their competencies at the industrial level, not individual companies, based on the p
- Policy
- Betmiga's first generic, Hemlibra registered next month
- by Kim, Jung-Ju Apr 24, 2020 06:26am
- 2 items including Mirabeg 50mg, which are the first generic drugs for overactive bladder, and Hemlibra 30mg for hemophilia treatment (Emicizumab) by JW Pharmaceutical are confirmed to be registered next month, and are added to the drug benefit standard. In addition, oral administration of Clopidogrel is acceptable for children with Kawasak
- Company
- Amid COVID-19, March drug export hits record high
- by Kim, Jin-Gu Apr 24, 2020 06:26am
- A monthly export volume of Korean pharmaceuticals has reached a record high in last March. Sources view the COVID-19 outbreak has not affected the pharmaceutical production and export significantly. According to the import and export statistics data published by Korea Customs Service (KCS), Korea has exported USD 538.09 million (approximatel
